期刊
CALCIFIED TISSUE INTERNATIONAL
卷 112, 期 4, 页码 452-462出版社
SPRINGER
DOI: 10.1007/s00223-023-01062-7
关键词
Cinacalcet; Parathyroid hormone; PTH; Diabetes; Osteoblasts
Patients with type 2 diabetes mellitus have a higher risk of fractures despite normal to high bone mineral density. This study investigated the effects of high glucose levels on human osteoblasts and tested the efficacy of parathyroid hormone and cinacalcet in promoting cell growth and matrix mineralization. The findings suggest that combination therapy with these two agents may ameliorate the negative impact of chronic high blood glucose on bone remodeling.
Patients with type 2 diabetes mellitus (T2DM) experience a higher risk of fractures despite paradoxically exhibiting normal to high bone mineral density (BMD). This has drawn into question the applicability to T2DM of conventional fracture reduction treatments that aim to retain BMD. In a primary human osteoblast culture system, high glucose levels (25 mM) impaired cell proliferation and matrix mineralization compared to physiological glucose levels (5 mM). Treatment with parathyroid hormone (PTH, 10 nM), a bone anabolic agent, and cinacalcet (CN, 1 mu M), a calcimimetic able to target the Ca2+-sensing receptor (CaSR), were tested for their effects on proliferation and differentiation. Strikingly, CN+PTH co-treatment was shown to promote cell growth and matrix mineralization under both physiological and high glucose conditions. CN+PTH reduced apoptosis by 0.9-fold/0.4-fold as measured by Caspase-3 activity assay, increased alkaline phosphatase (ALP) expression by 1.5-fold/twofold, increased the ratio of nuclear factor kappa-B ligand (RANKL) to osteoprotegerin (OPG) by 2.1-fold/1.6-fold, and increased CaSR expression by 1.7-fold/4.6-fold (physiological glucose/high glucose). Collectively, these findings indicate a potential for CN+PTH combination therapy as a method to ameliorate the negative impact of chronic high blood glucose on bone remodeling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据